Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2309415 | 0.99 | NPSR1 (0.48) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2311462 | 0.96 | KDM4E (0.48) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2307459 | 0.94 | NAMPT (0.46) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2312972 | 0.79 | JAK3 (0.46) | NPC1ALDH1A1KDM4ENPSR1LMNA | |
| SCHEMBL2281590 | 0.77 | CA1 (0.64) | ALDH1A1 | |
| SCHEMBL2311822 | 0.74 | FKBP5 (0.48) | NPC1GAASMN1; SMN2 | |
| SCHEMBL2313316 | 0.74 | JAK3 (0.47) | NPC1HPGDSMN1; SMN2 | |
| SCHEMBL22757547 | 0.73 | JAK3 (0.39) | — | |
| SCHEMBL2313546 | 0.73 | HTT (0.46) | ALDH1A1KDM4EHPGDHSD17B10NPSR1 | |
| SCHEMBL2310567 | 0.73 | NPC1 (0.51) | NPC1ALDH1A1KDM4EHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-9440994-B2 | Boron containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011019618-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | NPC1 216/4885ALDH1A1 4684/4885KDM4E 3726/4885 |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | BTD, BAD, BRI3BP | NPC1 216/4885ALDH1A1 4684/4885KDM4E 3726/4885 |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | NPC1 216/4885ALDH1A1 4684/4885KDM4E 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.